Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Today, we are moving to a logo with a new look & feel. Even if we were very keen on our « old » one, the time had come to change our identity.
Right from the beginning, the concept to make 360 changes were out of our mind. It was of a high importance to stick to key elements in order to still be identified as Oncodesign. That is why, we focused on an evolutive approach rather than a radical one.
Over the coming months, we will be harmonizing our graphic identity and updating the website and our documents.